Abbott Laboratories (ABT) EVP discloses share ownership and long-term options

Rhea-AI Filing Summary

Abbott Laboratories executive reports insider holdings

An executive vice president of Abbott Laboratories filed an ownership report as of 12/12/2025. The insider directly holds 63,621 common shares of Abbott Laboratories. In addition, the report lists several employee stock options granted under the Abbott Laboratories 2017 Incentive Stock Program, all classified as direct holdings.

The options cover blocks of Abbott common shares with exercise prices ranging from $75.90 to $135.42 per share and expiration dates from 02/21/2029 through 02/24/20352024 and 2028, reflecting the vesting schedules tied to long-term incentive compensation.

12/19/2025 - 04:39 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Scoggins Christopher J

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/12/2025

3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	63,621	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	02/21/2029	Common shares	51,557	$75.9	D
Option (right to buy)	(1)	03/31/2029	Common shares	43,388	$79.98	D
Option (right to buy)	(1)	02/20/2030	Common shares	68,578	$87.72	D
Option (right to buy)	(1)	02/18/2031	Common shares	63,991	$124.04	D
Option (right to buy)	(1)	02/17/2032	Common shares	48,852	$117.58	D
Option (right to buy)	(2)	02/16/2033	Common shares	37,483	$106.24	D
Option (right to buy)	(3)	02/20/2034	Common shares	31,721	$116.98	D
Option (right to buy)	(4)	02/24/2035	Common shares	45,730	$135.42	D

Explanation of Responses:

1. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,573 on February 21, 2025, 10,574 on February 21, 2026, and 10,574 on February 21, 2027.

4. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,243 on February 25, 2026, 15,243 on February 25, 2027, and 15,244 on February 25, 2028.

	/s/ Christopher J. Scoggins by Jessica H. Paik, Attorney-in-Fact	12/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider position is reported for Abbott Laboratories (ABT)?

The filing shows an executive vice president of Abbott Laboratories as the reporting person, disclosing their beneficial ownership of Abbott securities as of 12/12/2025.

How many Abbott Laboratories (ABT) common shares does the insider directly own?

The executive directly owns 63,621 common shares of Abbott Laboratories, reported as beneficially owned in direct form.

What stock options are reported by the Abbott (ABT) executive?

The report lists multiple employee stock options under the Abbott Laboratories 2017 Incentive Stock Program, each giving the right to buy Abbott common shares with different exercise prices and expiration dates.

What are the exercise prices and expirations of the reported Abbott (ABT) options?

Options cover Abbott common shares with exercise prices of $75.90, $79.98, $87.72, $124.04, $117.58, $106.24, $116.98, and $135.42, expiring between 02/21/2029 and 02/24/2035.

How many Abbott (ABT) shares underlie the reported stock options?

The options are for blocks of Abbott common shares, including 51,557, 43,388, 68,578, 63,991, 48,852, 37,483, 31,721, and 45,730 shares, each tied to a specific grant.

How do the Abbott (ABT) options vest under the 2017 Incentive Stock Program?

For certain grants, the filing specifies vesting in annual increments, such as 12,494/12,494/12,495 shares over three years, and similar three-year schedules like 10,573/10,574/10,574 and 15,243/15,243/15,244 shares.